Eli Lilly and [LLY] vs Amgen [AMGN] Detailed Stock Comparison

Eli Lilly and Company

NYSE
Loading...

Amgen Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Eli Lilly and Company wins in 11 metrics, Amgen Inc. wins in 10 metrics, with 0 ties. Eli Lilly and Company appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Eli Lilly and Company Amgen Inc. Better
P/E Ratio (TTM) 40.09 24.22 Amgen Inc.
Price-to-Book Ratio 31.01 21.46 Amgen Inc.
Debt-to-Equity Ratio 165.31 640.28 Eli Lilly and Company
PEG Ratio 0.79 0.22 Amgen Inc.
EV/EBITDA 26.61 13.97 Amgen Inc.
Profit Margin (TTM) 31.67% 20.98% Eli Lilly and Company
Operating Margin (TTM) 44.90% 30.55% Eli Lilly and Company
EBITDA Margin (TTM) 44.90% 30.55% Eli Lilly and Company
Return on Equity 101.16% 106.10% Amgen Inc.
Return on Assets (TTM) 19.42% 7.93% Eli Lilly and Company
Free Cash Flow (TTM) $5.96B $8.10B Amgen Inc.
Dividend Yield 0.60% 3.30% Amgen Inc.
1-Year Return 38.28% 20.32% Eli Lilly and Company
Price-to-Sales Ratio (TTM) 12.63 5.06 Amgen Inc.
Enterprise Value $843.37B $232.21B Eli Lilly and Company
EV/Revenue Ratio 12.94 6.32 Amgen Inc.
Gross Profit Margin (TTM) 82.52% 69.84% Eli Lilly and Company
Revenue per Share (TTM) $73 $68 Eli Lilly and Company
Earnings per Share (Diluted) $22.94 $14.24 Eli Lilly and Company
Beta (Stock Volatility) 0.50 0.47 Amgen Inc.
Short % of Float 0.97% 2.60% Eli Lilly and Company

Eli Lilly and Company vs Amgen Inc. Stock Performance Analysis

Loading Price Chart...

LLY
AMGN

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Eli Lilly and Company-0.32%-1.72%12.38%14.18%6.32%4.53%
Amgen Inc.-1.31%1.39%7.42%-4.29%7.75%6.99%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Eli Lilly and Company38.28%153.07%418.42%1,433.98%2,935.09%1,988.48%
Amgen Inc.20.32%54.66%48.82%137.40%512.31%431.58%

Performance & Financial Health Analysis: Eli Lilly and Company vs Amgen Inc.

MetricLLYAMGN
Market Information
Market Cap i$821.31B$187.93B
Market Cap CategoryMega capLarge cap
10 Day Avg. Volume i2,387,4762,431,753
90 Day Avg. Volume i2,777,7492,596,291
Last Close$1,129.35$350.53
52 Week Range$623.78 - $1,182.73$267.83 - $391.29
% from 52W High-4.51%-10.42%
All-Time High$1,182.73 (Jun 08, 2026)$391.29 (Mar 02, 2026)
% from All-Time High-4.51%-10.42%
Growth Metrics
Quarterly Revenue Growth0.43%0.09%
Quarterly Earnings Growth0.51%1.13%
Financial Health
Profit Margin (TTM) i0.32%0.21%
Operating Margin (TTM) i0.45%0.31%
Return on Equity (TTM) i1.01%1.06%
Debt to Equity (MRQ) i165.31640.28
Cash & Liquidity
Book Value per Share (MRQ)$29.66$16.07
Cash per Share (MRQ)$8.14$16.94
Operating Cash Flow (TTM) i$16.81B$9.96B
Levered Free Cash Flow (TTM) i$1.95B$7.50B
Dividends
Last 12-Month Dividend Yield i0.60%3.30%
Last 12-Month Dividend i$6.23$12.18

Valuation & Enterprise Metrics Analysis: Eli Lilly and Company vs Amgen Inc.

MetricLLY (Apr 24, 2026)AMGN (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i40.0924.22
Forward P/E i21.8214.77
PEG Ratio i0.790.22
Price to Sales (TTM) i12.635.06
Price to Book (MRQ) i31.0121.46
Market Capitalization
Market Capitalization i$821.31B$187.93B
Enterprise Value i$843.37B$232.21B
Enterprise Value Metrics
Enterprise to Revenue i12.946.32
Enterprise to EBITDA i26.6113.97
Risk & Other Metrics
Beta i0.500.47
Book Value per Share (MRQ) i$29.66$16.07

Financial Statements Comparison: Eli Lilly and Company vs Amgen Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricLLY (2025)AMGN (2025)
Revenue/Sales i65.18B36.75B
Cost of Goods Sold i11.05B12.04B
COGS % of Revenue i17.0%32.8%
Gross Profit i54.13B24.71B
Gross Margin i83.0%67.2%
Research & Development i13.34B7.27B
Operating Income (EBIT) i29.70B9.08B
Operating Margin i45.6%24.7%
EBITDA i35.09B16.90B
EBITDA Margin i53.8%46.0%
Pre-Tax Income i25.73B8.98B
Pre-Tax Income % of Revenue i39.5%24.4%
Income Tax i5.09B1.27B
Income Tax % of Revenue i7.8%3.4%
Net Income (Profit) i20.64B7.71B
Profit Margin i31.7%21.0%

Balance Sheet & Liquidity Metrics

MetricLLY (2025)AMGN (2025)
Cash & Equivalents i7.27B9.13B
Total Current Assets i55.63B29.06B
Total Current Assets % of Revenue i85.3%79.1%
Total Current Liabilities i35.23B25.49B
Total Current Liabilities % of Revenue i54.0%69.4%
Long-Term Debt i40.87B50.01B
Long-Term Debt % of Revenue i62.7%136.1%
Total Shareholders Equity i26.54B8.66B
Retained Earnings i24.47B-25.11B
Retained Earnings % of Revenue i37.5%-68.3%
Property, Plant & Equipment i13.49B5.22B

Cash Flow Statement Comparison

MetricLLY (2025)AMGN (2025)
Operating Cash Flow i23.60B10.51B
Operating Cash Flow % of Revenue i36.2%28.6%
Capital Expenditures i-7.84B-1.86B
Free Cash Flow i5.96B8.10B
FCF Margin i9.2%22.0%
Debt Repayment i-778.00M-5.00B
Common Stock Repurchase i-4.11B0

Short Interest & Institutional Ownership Analysis

MetricLLYAMGN
Shares Short i7.70M13.98M
Short Ratio i2.735.43
Short % of Float i0.97%2.60%
Shares Outstanding i894.80M538.80M
Float Shares i890.99M537.62M
% Held by Insiders i0.17%0.22%
% Held by Institutions i84.77%85.36%
% Held by Public i15.06%14.42%

Dividend Analysis & Yield Comparison: Eli Lilly and Company vs Amgen Inc.

MetricLLYAMGN
Last 12-Month Dividend i$6.23$12.18
Last 12-Month Dividend Yield i0.60%3.30%
3-Year Avg Annual Dividend i$5.44$9.98
3-Year Avg Dividend Yield i0.18%0.77%
3-Year Total Dividends i$16.32$29.95
Ex-Dividend DateFeb 13, 2026May 15, 2026